TScan Therapeutics (NASDAQ:TCRX) Rating Increased to Hold at Wall Street Zen

TScan Therapeutics (NASDAQ:TCRX) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Other research analysts have also issued reports about the stock. HC Wainwright decreased their price target on shares of TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. Wedbush reiterated an “outperform” rating and issued a $7.00 price target on shares of TScan Therapeutics in a research note on Tuesday, May 6th. Morgan Stanley reissued an “overweight” rating and set a $10.00 price objective on shares of TScan Therapeutics in a research report on Friday, March 14th. Finally, Needham & Company LLC reissued a “buy” rating and set a $9.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, April 8th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $7.80.

TScan Therapeutics Trading Down 1.6%

NASDAQ:TCRX opened at $1.81 on Friday. The company has a fifty day moving average of $1.50 and a 200 day moving average of $1.83. TScan Therapeutics has a 52 week low of $1.02 and a 52 week high of $7.89. The company has a quick ratio of 8.55, a current ratio of 8.55 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $102.43 million, a P/E ratio of -1.66 and a beta of 0.97.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 2,974.08% and a negative return on equity of 55.76%. The company had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.62 million. On average, research analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current year.

Insider Activity

In related news, major shareholder Lynx1 Capital Management Lp acquired 1,200,000 shares of TScan Therapeutics stock in a transaction dated Tuesday, May 20th. The shares were purchased at an average price of $1.20 per share, for a total transaction of $1,440,000.00. Following the completion of the transaction, the insider directly owned 7,946,141 shares in the company, valued at approximately $9,535,369.20. This represents a 17.79% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.35% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN grew its holdings in shares of TScan Therapeutics by 41.1% in the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock valued at $59,000 after purchasing an additional 5,694 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of TScan Therapeutics by 5.2% in the fourth quarter. Wellington Management Group LLP now owns 132,895 shares of the company’s stock valued at $404,000 after acquiring an additional 6,550 shares in the last quarter. Woodline Partners LP raised its holdings in shares of TScan Therapeutics by 6.7% in the fourth quarter. Woodline Partners LP now owns 115,866 shares of the company’s stock valued at $352,000 after acquiring an additional 7,282 shares in the last quarter. Aberdeen Group plc raised its holdings in shares of TScan Therapeutics by 0.9% in the first quarter. Aberdeen Group plc now owns 891,448 shares of the company’s stock valued at $1,230,000 after acquiring an additional 7,744 shares in the last quarter. Finally, Barclays PLC raised its holdings in shares of TScan Therapeutics by 16.3% in the fourth quarter. Barclays PLC now owns 67,508 shares of the company’s stock valued at $206,000 after acquiring an additional 9,441 shares in the last quarter. 82.83% of the stock is owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.